SB5 adalimumab biosimilar in the treatment of psoriasis and psoriatic arthritis

Dermatol Ther. 2020 May;33(3):e13435. doi: 10.1111/dth.13435. Epub 2020 May 11.

Authors

Antonella Di Cesare¹, Greta Tronconi¹, Thais M Fastame¹, Elia Rosi¹, Leonardo Pescitelli¹, Federica Ricceri¹, Francesca Prignano¹

Affiliation

¹ Department of Health Sciences, Section of Dermatology, University of Florence, Florence, Italy.

PMID: 32306527
DOI: 10.1111/dth.13435

No abstract available

Publication types

Letter

MeSH terms

Adalimumab / adverse effects
Antirheumatic Agents* / adverse effects
Arthritis, Psoriatic* / diagnosis
Arthritis, Psoriatic* / drug therapy
Biosimilar Pharmaceuticals* / adverse effects
Humans
Psoriasis* / diagnosis
Psoriasis* / drug therapy

Substances

Antirheumatic Agents
Biosimilar Pharmaceuticals
Adalimumab